Fennec Pharmaceuticals is trading at $10.25 (-8.2%) in pre-market, pulling back after a strong multi-day run as investors continue to digest recent financial results.
- Sentiment remains impacted by a Q4 2025 earnings miss and widened net loss, which previously triggered sharp swings and raised questions regarding the company's valuation and path to profitability.
- With no fresh company-specific headlines reported this morning, the move appears to be driven by continued market repositioning following the stock's recent rally.